Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults.


Journal

Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676

Informations de publication

Date de publication:
15 Mar 2023
Historique:
received: 18 05 2022
accepted: 17 02 2023
entrez: 16 3 2023
pubmed: 17 3 2023
medline: 17 3 2023
Statut: epublish

Résumé

Saliva is easily obtainable non-invasively and potentially suitable for detecting both current and previous SARS-CoV-2 infection, but there is limited evidence on the utility of salivary antibody testing for community surveillance. We established 6 ELISAs detecting IgA and IgG antibodies to whole SARS-CoV-2 spike protein, to its receptor binding domain region and to nucleocapsid protein in saliva. We evaluated diagnostic performance, and using paired saliva and serum samples, correlated mucosal and systemic antibody responses. The best-performing assays were field-tested in 20 household outbreaks. We demonstrate in test accuracy (N = 320), spike IgG (ROC AUC: 95.0%, 92.8-97.3%) and spike IgA (ROC AUC: 89.9%, 86.5-93.2%) assays to discriminate best between pre-pandemic and post COVID-19 saliva samples. Specificity was 100% in younger age groups (0-19 years) for spike IgA and IgG. However, sensitivity was low for the best-performing assay (spike IgG: 50.6%, 39.8-61.4%). Using machine learning, diagnostic performance was improved when a combination of tests was used. As expected, salivary IgA was poorly correlated with serum, indicating an oral mucosal response whereas salivary IgG responses were predictive of those in serum. When deployed to household outbreaks, antibody responses were heterogeneous but remained a reliable indicator of recent infection. Intriguingly, unvaccinated children without confirmed infection showed evidence of exposure almost exclusively through specific IgA responses. Through robust standardisation, evaluation and field-testing, this work provides a platform for further studies investigating SARS-CoV-2 transmission and mucosal immunity with the potential for expanding salivo-surveillance to other respiratory infections in hard-to-reach settings. If a person has been previously infected with SARS-CoV-2 they will produce specific proteins, called antibodies. These are present in the saliva and blood. Saliva is easier to obtain than blood, so we developed and evaluated six tests that detect SARS-CoV-2 antibodies in saliva in children and adults. Some tests detected antibodies to a particular protein made by SARS-CoV-2 called the spike protein, and these tests worked best. The most accurate results were obtained by using a combination of tests. Similar tests could also be developed to detect other respiratory infections which will enable easier identification of infected individuals.

Sections du résumé

BACKGROUND BACKGROUND
Saliva is easily obtainable non-invasively and potentially suitable for detecting both current and previous SARS-CoV-2 infection, but there is limited evidence on the utility of salivary antibody testing for community surveillance.
METHODS METHODS
We established 6 ELISAs detecting IgA and IgG antibodies to whole SARS-CoV-2 spike protein, to its receptor binding domain region and to nucleocapsid protein in saliva. We evaluated diagnostic performance, and using paired saliva and serum samples, correlated mucosal and systemic antibody responses. The best-performing assays were field-tested in 20 household outbreaks.
RESULTS RESULTS
We demonstrate in test accuracy (N = 320), spike IgG (ROC AUC: 95.0%, 92.8-97.3%) and spike IgA (ROC AUC: 89.9%, 86.5-93.2%) assays to discriminate best between pre-pandemic and post COVID-19 saliva samples. Specificity was 100% in younger age groups (0-19 years) for spike IgA and IgG. However, sensitivity was low for the best-performing assay (spike IgG: 50.6%, 39.8-61.4%). Using machine learning, diagnostic performance was improved when a combination of tests was used. As expected, salivary IgA was poorly correlated with serum, indicating an oral mucosal response whereas salivary IgG responses were predictive of those in serum. When deployed to household outbreaks, antibody responses were heterogeneous but remained a reliable indicator of recent infection. Intriguingly, unvaccinated children without confirmed infection showed evidence of exposure almost exclusively through specific IgA responses.
CONCLUSIONS CONCLUSIONS
Through robust standardisation, evaluation and field-testing, this work provides a platform for further studies investigating SARS-CoV-2 transmission and mucosal immunity with the potential for expanding salivo-surveillance to other respiratory infections in hard-to-reach settings.
If a person has been previously infected with SARS-CoV-2 they will produce specific proteins, called antibodies. These are present in the saliva and blood. Saliva is easier to obtain than blood, so we developed and evaluated six tests that detect SARS-CoV-2 antibodies in saliva in children and adults. Some tests detected antibodies to a particular protein made by SARS-CoV-2 called the spike protein, and these tests worked best. The most accurate results were obtained by using a combination of tests. Similar tests could also be developed to detect other respiratory infections which will enable easier identification of infected individuals.

Autres résumés

Type: plain-language-summary (eng)
If a person has been previously infected with SARS-CoV-2 they will produce specific proteins, called antibodies. These are present in the saliva and blood. Saliva is easier to obtain than blood, so we developed and evaluated six tests that detect SARS-CoV-2 antibodies in saliva in children and adults. Some tests detected antibodies to a particular protein made by SARS-CoV-2 called the spike protein, and these tests worked best. The most accurate results were obtained by using a combination of tests. Similar tests could also be developed to detect other respiratory infections which will enable easier identification of infected individuals.

Identifiants

pubmed: 36922542
doi: 10.1038/s43856-023-00264-2
pii: 10.1038/s43856-023-00264-2
pmc: PMC10016188
doi:

Types de publication

Journal Article

Langues

eng

Pagination

37

Subventions

Organisme : RCUK | Medical Research Council (MRC)
ID : MR/V028545/1
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/V038613/1
Organisme : RCUK | Medical Research Council (MRC)
ID : MC/PC/19067
Organisme : Wellcome Trust (Wellcome)
ID : 217509/Z/19/Z
Organisme : Wellcome Trust (Wellcome)
ID : 202802/Z/16/Z

Investigateurs

Hanin Alamir (H)
Holly E Baum (HE)
Anu Goenka (A)
Alice Halliday (A)
Ben Hitchings (B)
Elizabeth Oliver (E)
Debbie Shattock (D)
Joyce Smith (J)
Amy C Thomas (AC)
David Adegbite (D)
Rupert Antico (R)
Jamie Atkins (J)
Edward Baxter (E)
Lindsay Bishop (L)
Adam Boon (A)
Emma Bridgeman (E)
Lucy Collingwood (L)
Catherine Derrick (C)
Leah Fleming (L)
Ricardo Garcia Garcia (RG)
Guillaume Gonnage Liveria (GG)
Niall Grace (N)
Lucy Grimwood (L)
Jane Kinney (J)
Rafaella Myrtou (R)
Alice O'Rouke (A)
Jenny Oliver (J)
Chloe Payne (C)
Rhian Pennie (R)
Millie Powell (M)
Laura Ratero Garcia (LR)
Aoife Storer-Martin (A)
John Summerhill (J)
Amy Taylor (A)
Zoe Taylor (Z)
Helen Thompson (H)
Samantha Thomson-Hill (S)
Louis Underwood (L)
Gabriella Valentine (G)
Stefania Vergnano (S)
Amelia Way (A)
Maddie White (M)
Arthur Williams (A)
David Allen (D)
Josh Anderson (J)
Mariella Ardeshir (M)
Michael Booth (M)
Charles Butler (C)
Monika Chaulagain (M)
Alex Darling (A)
Nicholas Dayrell-Armes (N)
Kaltun Duale (K)
Malak Eghleilib (M)
Chloe Farren (C)
Danny Freestone (D)
Jason Harkness (J)
William Healy (W)
Milo Jeenes Flanagan (MJ)
Maria Khalique (M)
Nadine King (N)
Anna Koi (A)
Maia Lyall (M)
Begonia Morales-Aza (B)
Maria Pozo (M)
Ainhoa Rodriguez Pereira (AR)
Jessica Rosa (J)
Louise Setter (L)
Liam Thomas (L)
Dylan Thomas (D)
Jonathan Vowles (J)

Informations de copyright

© 2023. The Author(s).

Références

J Hyg (Lond). 1985 Aug;95(1):173-89
pubmed: 2991366
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9
pubmed: 33221383
Nature. 2020 Aug;584(7820):274-278
pubmed: 32760003
Microbiol Spectr. 2021 Oct 31;9(2):e0073121
pubmed: 34523985
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Mucosal Immunol. 2016 Jul;9(4):884-93
pubmed: 26509875
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Lancet Microbe. 2021 Feb;2(2):e60-e69
pubmed: 33521709
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Nat Commun. 2021 Oct 27;12(1):6197
pubmed: 34707161
Viruses. 2022 Jul 08;14(7):
pubmed: 35891471
Cell Rep Med. 2021 Jul 20;2(7):100327
pubmed: 34124701
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Science. 2020 Nov 6;370(6517):725-730
pubmed: 32958580
Nucleic Acids Res. 2012 Aug;40(15):e115
pubmed: 22730293
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
JAMA Netw Open. 2022 Mar 1;5(3):e221313
pubmed: 35262717
J Infect. 2021 Jul;83(1):104-111
pubmed: 33933527
Front Immunol. 2020 Nov 30;11:611337
pubmed: 33329607
Nat Commun. 2021 Sep 23;12(1):5621
pubmed: 34556667
BMJ. 2020 Nov 11;371:m4262
pubmed: 33177070
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nat Med. 2022 Nov;28(11):2416-2423
pubmed: 36302894
EBioMedicine. 2021 Jun;68:103414
pubmed: 34098341
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33067270
Front Immunol. 2022 Nov 09;13:968317
pubmed: 36439154
Infect Immun. 1981 Sep;33(3):697-703
pubmed: 7287178
mBio. 2021 Oct 26;12(5):e0190821
pubmed: 34544278
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
Ann N Y Acad Sci. 2007 Mar;1098:288-311
pubmed: 17435136
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
Mucosal Immunol. 2020 Jan;13(1):12-21
pubmed: 31740744
J Immunol. 2022 Mar 15;208(6):1500-1508
pubmed: 35228262
Microbiol Spectr. 2022 Feb 23;10(1):e0151221
pubmed: 35171028
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Oral Microbiol. 2013;5:
pubmed: 23487566
Nat Commun. 2021 May 25;12(1):3109
pubmed: 34035301

Auteurs

Amy C Thomas (AC)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. amyc.thomas@bristol.ac.uk.
Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. amyc.thomas@bristol.ac.uk.

Elizabeth Oliver (E)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Holly E Baum (HE)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Kapil Gupta (K)

School of Biochemistry, University of Bristol, Bristol, UK.
BrisSynBio, University of Bristol, Bristol, UK.
Imophoron Ltd, Science Creates, Old Market, Midland Road, Bristol, UK.

Kathryn L Shelley (KL)

School of Biochemistry, University of Bristol, Bristol, UK.
BrisSynBio, University of Bristol, Bristol, UK.
School of Chemistry, University of Bristol, Bristol, UK.

Anna E Long (AE)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Hayley E Jones (HE)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Joyce Smith (J)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Benjamin Hitchings (B)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Natalie di Bartolo (N)

School of Biochemistry, University of Bristol, Bristol, UK.
NIHR Blood and Transplant Research Unit in Red Cell Products, University of Bristol, Bristol, UK.

Kate Vasileiou (K)

School of Biochemistry, University of Bristol, Bristol, UK.

Fruzsina Rabi (F)

School of Biochemistry, University of Bristol, Bristol, UK.

Hanin Alamir (H)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Malak Eghleilib (M)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Ore Francis (O)

Bristol Veterinary School, University of Bristol, Bristol, UK.

Jennifer Oliver (J)

Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.

Begonia Morales-Aza (B)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Ulrike Obst (U)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Debbie Shattock (D)

Bristol Bioresource Laboratories, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Rachael Barr (R)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8BJ, UK.

Lucy Collingwood (L)

Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.

Kaltun Duale (K)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Niall Grace (N)

Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.

Guillaume Gonnage Livera (GG)

Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.

Lindsay Bishop (L)

Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK.

Harriet Downing (H)

NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK.

Fernanda Rodrigues (F)

Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal.

Nicholas Timpson (N)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, Bristol, UK.

Caroline L Relton (CL)

MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, Bristol, UK.

Ashley Toye (A)

School of Biochemistry, University of Bristol, Bristol, UK.
NIHR Blood and Transplant Research Unit in Red Cell Products, University of Bristol, Bristol, UK.

Derek N Woolfson (DN)

School of Biochemistry, University of Bristol, Bristol, UK.
BrisSynBio, University of Bristol, Bristol, UK.
School of Chemistry, University of Bristol, Bristol, UK.

Imre Berger (I)

Max Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol, UK.

Anu Goenka (A)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Paediatric Immunology & Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK.

Andrew D Davidson (AD)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Kathleen M Gillespie (KM)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Alistair J K Williams (AJK)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Mick Bailey (M)

Bristol Veterinary School, University of Bristol, Bristol, UK.

Ellen Brooks-Pollock (E)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Adam Finn (A)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Paediatric Immunology & Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK.

Alice Halliday (A)

Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Classifications MeSH